Introduction

I
ntegrins are a family of cell surface adhesion receptors consisting of two heterodimeric subunits (α and β), with function to promote invasion and support survival, as well as to regulate cell adhesion [1, 2] . As an important member of this family, integrin α v β 3 is generally not found in normal tissues but is highly expressed on activated endothelial cells during tumor angiogenesis, as well as some tumor cells, such as late-stage glioblastomas, breast and prostate tumors, malignant melanomas, and ovarian carcinomas [3] [4] [5] . Increased expression of integrin α v β 3 is closely associated with tumor biological activities, including angiogenesis, cell adhesion, invasion, and metastasis [6, 7] . Inhibition of integrin α v β 3 function using blocking monoclonal antibodies, peptide antagonists, and small peptide mimetics matrix has been shown to be a promising strategy for antiangiogenic cancer therapy [8] [9] [10] .
In the past decade, radiolabeled arginine-glycine-aspartic acid (RGD) peptides and analogs have been wildly investigated for noninvasive imaging of tumor integrin α v β 3 expression in both animal models and clinical trials [11] [12] [13] [14] , based on the recognition between RGD and integrin α v β 3 . In addition to RGD peptides, anti-integrin α v β 3 antibodies were also generated and evaluated as integrin α v β 3 -targeting vehicles. Abegrin™, also known as MEDI-522 or Vitaxin™, is a humanized monoclonal antibody against human integrin α v β 3 , which is currently in clinical trials for the treatment of stage IV metastatic melanoma and androgen-independent prostate cancer [15, 16] . Unlike other antibodies, Abegrin™ recognizes the integrin α v and β 3 subunits as one entity [16, 17] , which makes it much more specific for integrin α v β 3 [18] . In a recent clinical study, Abegrin™ was well tolerated with no evidence of immunogenicity in patients with advanced solid tumors, which guaranteed its further clinical investigation [19] .
Radiolabeled monoclonal antibodies have been developed for both diagnosis and therapy of tumors. We recently reported the radioimmunotherapy of 90 Y-labeled Abegrin™ in the glioblastoma tumor model [8] . The 99m Tc-labeled hLM609-I, the earlier version of Abegrin™, was previously tested for the in vivo imaging of tumor vasculature. However, the imaging was unsuccessful due to the instability of 99m Tc labeling [20] . Cai et al. recently evaluated the in vitro and in vivo characterizations of 64 Cu (t 1/2 = 12.7 h; β + , 17%; β − , 39%)-labeled Abegrin™ in nude mouse tumor models. The probe showed high and specific tumor uptake in integrin α v β 3 -positive tumors, which makes the 64 Cu-labeled tracer promising for evaluating the pharmacokinetics, tumor targeting efficacy, and dose optimization of Abegrin™ [21] . Comparing with 64 Cu, 111 In (t 1/2 = 2.8 days; γ, 173 keV, 89%; 247 keV, 94%) possesses more suitable half-life for antibody-based tumor imaging, which allows a long-term observation of the in vivo behaviors and clinical imaging with a gamma camera or single photon emission computed tomography (SPECT). Nowadays, a series of 111 In-labeled antibodies have been used in clinical trials for tumor imaging and monitoring the therapeutic efficacy of anticancer drugs [22] [23] [24] [25] . In this study, we labeled Abegrin™ with 111 In using 1,4,7,10-tetraazadodecane-N,N′,N″,N′″-tetraacetic acid (DOTA) as the chelator, tested the in vitro immunoreactivity and affinity, and investigated the in vivo tumor targeting properties in integrin α v β 3 -positive U87MG tumors and also in integrin α v β 3 -negative HT-29 tumors.
Materials and Methods
Materials and Reagents
The humanized anti-integrin α v β 3 monoclonal antibody (mAb) Abegrin™ (MEDI-522 or Vitaxin™) was obtained from MedImmune, Inc. (Gaithersburg, MD). Macrocyclic chelating agent DOTA was purchased from Macrocyclics, Inc. (Dallas, TX). 1-Ethyl-3-[3-(dimethylamino)-propyl] carbodiimide (EDC) and N-hydroxysulfonosuccinimide (SNHS) were purchased from Aldrich (St. Louis, MO).
111
InCl 3 was obtained from Perkin-Elmer Life and Analytical Sciences (North Billarica, MA). PD-10 desalting columns were purchased from GE Healthcare (Piscataway, NJ). All water and buffers used for DOTA conjugation and radiolabeling were passed through a Chelex 100 (Sigma-Aldrich, St. Louis, MO) column to minimize the trace metal contaminants.
Cell Culture and Animal Models
U87MG human glioblastoma cells and HT-29 human colon cancer cells were obtained from American Type Culture Collection (Manassas, VA). U87MG cells were cultured in low glucose Dulbecco's Modified Eagle's Medium (DMEM) [21] , and HT-29 cells were cultured in high-glucose DMEM culture medium [26] . Both cell lines were cultured in medium supplemented with 10% (v/v) fetal bovine serum at 37°C in a humidified atmosphere with 5% CO 2 . Female BALB/c nude mice (4∼5 weeks of age) were purchased from the Department of Experimental Animal, Peking University Health Science Center. All animal experiments were performed in accordance with guidelines of Peking University Health Science Center Animal Care Committee (Institutional Animal Care and Use Committee at Peking University). U87MG tumor model was established by subcutaneous injection of 2×10 6 U87MG tumor cells into the right upper flanks of nude mice. When the tumor volume reached 200∼300 mm 3 (3∼4 weeks after inoculation), the U87MG tumor-bearing nude mice were used for biodistribution studies. To establish another tumor model bearing both U87MG and HT-29 tumor xenografts, the U87MG cells (2×10 6 ) were first inoculated subcutaneously into the right upper flanks of mice. After about 15 days, HT-29 cells (5×10 6 ) were inoculated subcutaneously into left upper flanks of the same nude mice. In this condition, the two tumors reached a similar volume (200∼300 mm 3 ) after another 13 days, and then they were used for in vivo studies.
Saturation Binding Assay
The binding affinity of mAb Abegrin™ for integrin α v β 3 and the available binding sites per U87MG cell were measured by saturation binding assay [27] . Briefly, 125 I-Abegrin™ was generated by incubating Abegrin™ (50 μg) with Na 125 I (37 MBq) in a vial coated with Iodogen (Sigma-Aldrich, St. Louis, MO) and then purified by a PD-10 column using a previously described method [28] . U87MG cells were seeded in a Filter multiscreen DV plate (96-well; pore size, 0.65 μm; Millipore) and then incubated with increasing concentrations of 125 I-Abegrin™ (from 0.033 to 16.67 nM) in binding buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1 mM MnCl 2 , and 0.1% BSA). The total volume was adjusted to 200 μL using binding buffer. For each concentration, nonspecific binding was determined in the presence of an excess (9100-fold) unlabeled mAb Abegrin™. After 4 h of incubation at 4°C, the plate was filtered through a multiscreen vacuum manifold and washed five times with cold phosphate-buffered saline (PBS). The hydrophilic polyvinylidenedifluoride (PVDF) filters were collected, and the radioactivity was determined using a NaI (Tl) γ-counter (Wallac 1470-002, Perkin-Elmer, Finland). A saturation binding curve and Scatchard transformation were obtained by a nonlinear regression analysis, and the dissociation constant (K d ) value of 125 I-Abegrin™ and the binding sites per U87MG cell were determined using GraphPad Prism 4.0 (GraphPad Software, San Diego, CA). Each data point represents the average value from triplicate wells.
DOTA Conjugation and 111
In Radiolabeling
Abegrin™ was conjugated with DOTA as previously described [21] . Briefly, DOTA was activated by EDC and SNHS at pH 5.5 for 30 min at 4°C with a molar ratio of 10:5:4 (DOTA/EDC/SNHS). The DOTA-N-hydroxysulfosuccinimidyl (OSSu) was then added to Abegrin™ at the molar ratio of DOTA-OSSu/Abegrin™=200:1 in the bicarbonate buffer (pH = 9.0). After incubating overnight at 4°C, the DOTAAbegrin™ conjugates were then purified by PD-10 column and concentrated by Centricon filter (Millipore, Bedford, MA), and the final concentration was determined using a micro-BCA protein assay kit (Pierce Biotechnology).
For 111 In radiolabeling, 74 MBq of 111 InCl 3 (2 mCi) was diluted in 300 μL of 0.2 M sodium acetate buffer (pH 5.5) and added to 50 μg of DOTA-Abegrin™. The reaction mixture was incubated for 1 h at 39°C with constant shaking.
111 In-DOTAAbegrin™ was then purified by PD-10 column using PBS as the mobile phase.
Immunoreactivity and Specificity
The immunoreactivity of DOTA-Abegrin™ and intact Abegrin™ to integrin α v β 3 was evaluated by whole-cell displacement assay [29] . The U87MG cells were incubated with 125 I-Abegrin in the presence of increasing concentrations of Abegrin™ or DOTA-Abegrin™ in a 96-well filter plate. After 2 h of reaction at 4°C, the plates were washed, then the PVDF filters were collected, and measured in a γ-counter as described above. The best-fit 50% inhibitory concentration (IC 50 ) values were calculated by fitting the data with nonlinear regression using Graph Pad Prism 4.0 (GraphPad Software, Inc.). Experiments were performed twice with triplicate samples.
The integrin binding specificity of 111 In-DOTA-Abegrin™ was tested using U87MG cells. U87MG cells were seeded in six-well plates and incubated overnight at 37°C to allow adherence. After washing with PBS, 250 μL of the 111 In-DOTA-Abegrin solution (10 ng/mL in culture medium) was added to the wells of the plate with or without an excess amount of cold Abegrin™ (5 μg/mL). The cells were then incubated at 4°C for 2 h, after which the cells were washed and then collected by trypsinizing with 0.25% trypsin solution. The cell-associated radioactivity was measured in γ-counter.
Results were expressed as percentage of the total added dose per million cells (%AD/10 6 cells). Experiments were carried out twice with the triplicate samples.
Immunofluorescent Staining
The immunofluorescent staining of tumor cells were performed as we previously described [21, 30] . Briefly, U87MG or HT-29 cells were incubated with Abegrin™ (2 μg/mL) for 1 h at room temperature. After washing, the cells were visualized with Cy3-labeled donkey antihuman IgG (1:500) under the microscope (Carl Zeiss Axiovert 200 M, Carl Zeiss, Thornwood, NY).
U87MG and HT-29 tumor tissue sections (5 μm-thick) were cut from the frozen blocks, mounted on coated slides, fixed in acetone for 10 min, and allowed to dry in the air for 30 min. The sections were blocked with 10% donkey serum for 1 h at room temperature. For murine integrin α v β 3 and human integrin α v β 3 double staining, the sections were incubated with hamster antimouse integrin β 3 (1:100; BD Biosciences, San Jose, CA) and Abegrin™ (10 μg/mL) for 1 h at room temperature. After incubating with Cy3-conjugated donkey antihamster secondary antibody 
Integrin α v β 3 Expression on Tumor Cells
The U87MG and HT-29 cells grown in 24-well plates (1 × 10 5 /well) were incubated with ∼80,000 cpm of 125 I-Abegrin™. For each cell line, nonspecific binding was determined in the presence of an excess (9100-fold) unlabeled Abegrin™. The total volume was adjusted to 250 μL with 1% bovine serum albumin (in PBS). After incubating for 3 h at 4°C, the cells in the plate were washed gently with PBS for three times and then solubilized with 2 M NaOH. The cell-associated activity was measured in a γ-counter. Experiments were carried out twice with triplicate wells. Results were expressed as percentage of added dose per million cells (%AD/10 6 cells).
Planar γ Imaging
Each nude mouse bearing both U87MG and HT-29 tumor xenografts was injected with ∼11.1 MBq (300 μCi) of 111
In-DOTA-Abegrin™ via tail vein (n = 3). Animals were anesthetized with intraperitoneal injection of sodium pentobarbital at a dose of 45.0 mg/kg and then placed prone on a two-headed camera (SIEMENS, E. CAM) equipped with a parallel-hole, middle-energy, and high-resolution collimator. Posterior images were acquired at 2, 24, 48, and 120 h postinjection (p.i.) and stored digitally in a 128×128 matrix. The acquisition count limits were set at 200 K.
In Vivo Microdistribution of FITC-Abegrini in Tumors
Abegrin™ was conjugated with FITC-NHS (Pierce, Rockford, IL, USA) according to the standard protocol and purified with PD-10 column. The F/P ratio (fluorochrome/protein ratio, i.e., FITC-to-Abegrin™ ratio) of FITC-Abegrin™ after purification was measured based on UV absorbance using the following equation 
Biodistribution and Blocking Studies
Female nude mice bearing U87MG xenografts were injected with 0.74 MBq (20 μCi) of 111 In-DOTA-Abegrin™ via tail vein to evaluate the distribution of the tracer in the major organs of mice. At 4, 24, 72, 120, and 168 h p.i., mice were sacrificed. Blood, tumor, major organs, and tissues were collected, wet-weighted, and measured using a γ counter. The results were presented as percentage of injected dose per gram of tissue (%ID/g). Values are expressed as means±SD for a group of four animals (n=4 per group). A blocking study was also performed in a group of four mice by coinjecting 111 In-DOTA-Abegrin™ with 400 μg unlabeled Abegrin™. At 24 h p.i., all four animals were sacrificed for determination of organ biodistribution as described above.
Results
Saturation Binding Assay
The saturation binding curve and the Scatchard transformation of 125 I-Abegrin™ on U87MG cells are shown in Fig. 1a , b. The K d value for 125 I-Abegrin™ was determined to be 0.35±0.06 nM, and the maximum number of binding sites (B max ) was 2.5 × 10 5 receptors per U87MG cell, indicating the high affinity of Abegrin™ for integrin α v β 3 and high expression level of integrin α v β 3 on the U87MG cell surface. 
Immunoreactivity and Binding Specificity
The immunoreactivity of DOTA-Abegrin™ was compared with Abegrin™ by competition binding assay using 125 I-Abegrin™ as a radioligand. As shown in Fig. 1c , no obvious difference was observed between the DOTAAbegrin™ and Abegrin™, indicating that DOTA conjugation had minimal effect on the immunoreactivity of Abegrin™.
The binding of 111 In-DOTA-Abegrin™ to U87MG cells can be significantly inhibited by adding an excess dose of Abegrin™, demonstrating the in vitro specific binding of 111 In-DOTA-Abegrin™ to integrin α v β 3 on U87MG cells (Fig. 1d) .
Integrin α v β 3 Expression on Tumor Cells
The expression of integrin α v β 3 on U87MG and HT-29 cells was detected by fluorescent staining and radioligand binding assay. As shown in Fig. 2a , Abegrin™ bound strongly to U87MG cells but not HT-29 cells. Prominently, the specific staining of Abegrin™ was observed mostly on the cell membrane as integrin α v β 3 is mainly expressed on the cell surface. The binding fraction of 125 I-Abegrin™ on U87MG was about 30%AD/10 6 cells, and the cell-bound 125 I-Abegrin™ was significantly blocked by adding an excess dose of cold Abegrin™, indicating the specific binding of 125 I-Abegrin™ on U87MG cells (Fig. 2b) . In contrast, HT-29 cells can bind 125 I-Abegrin™ only at an extremely low level, which was consistent with the result shown in Fig. 2a . Overall, integrin α v β 3 is highly expressed on U87MG cells but lowly or nonexpressed on HT-29 cells.
Immunofluorescence Staining of U87MG and HT-29 Tumor Tissues
U87MG and HT-29 frozen tumor sections were stained for human integrin α v β 3 and mouse integrin α v β 3 . As shown in Fig. 2c , U87MG tumors were found to be positive for human integrin α v β 3 , while HT-29 tumors did not express human integrin α v β 3 , which was consistent with the above cell results. Both U87MG and HT-29 tumor tissues expressed murine 
Planar γ Imaging
The representative planar γ images acquired at several time points after injection of 111 In-DOTA-Abegrin™ are shown in Fig. 3a . Note that although both posterior and anterior images could be acquired simultaneously by the two-headed camera, we only showed the representative posterior images here because they were closer to the mice and had less blurred images than the anterior images. At 2 h postinjection, radioactivity was mainly accumulated in the heart and abdomen. The U87MG (right) and HT-29 (left) tumors were gradually visualized from 24 h postinjection. With the clearance of the radiotracer from normal organs, the tumor visualization was clearer, and the activity accumulation in U87MG tumors was higher than that in HT-29 tumors. At 120 h postinjection, the U87MG tumors showed high contrast of activity accumulation, which was significantly higher than that of HT-29 tumors. Liver is also visible due to the liver clearance of 111 In-DOTA-Abegrin™.
In Vivo Microdistribution of FITC-Abegrin™ in Tumors
To investigate the in vivo microdistribution of Abegrin™ in tumors, we labeled Abegrin™ with FITC. FITC-Abegrin™ was injected into nude mouse bearing both U87MG and HT-29 tumors, and the mouse was sacrificed at 24 h postinjection. The tumors and normal organs slices were costained with CD31. We performed the in vivo microdistribution study at 24 h p.i. because the tumor uptake of Abegrin™ at 24 h p.i. could reach a high level (similar to that at 72 h p.i., see below the ex vivo biodistribution data).
Most importantly, we believe that the in vivo stability of FITC-Abegrin™ at 24 h p.i. was much better than that at 72 h p.i. so that the fluorescent signal determined by microdistribution study may truly reflect the Abegrin™ Fig. 3 . a Nude mice bearing both U87MG and HT-29 tumor xenografts were injected intravenously with ∼300 μCi of 111 In-DOTA-Abegrin™, and then planar γ images were acquired at 2, 24, 48, and 120 h postinjection. Arrows indicate the tumor location; b FITC-Abegrin™ was injected intravenously into nude mice bearing both U87MG and HT-29 tumor xenografts. At 24 h postinjection, the tumors were cut into slices and then stained with antimouse CD31 antibody. location in tumors. As shown in Fig. 3b , both U87MG and HT-29 tumors showed predominant CD31 positive staining, indicating the high density of tumor vasculature in both of two tumors. The distribution of FITC-Abegrin™ in HT-29 tumor was almost localized around the tumor vasculature as determined by the good overlay of FITC with CD31. In contrast, besides the localization around the blood vessels, FITC-Abegrin™ also showed predominant tumor cell staining on U87MG tumors, indicating that FITC-Abegrin™ could bind to the U87MG tumor cells in vivo.
Biodistribution Studies
Biodistribution of 111 In-DOTA-Abegrin™ was determined in nude mice bearing U87MG tumors, and the results are shown in Fig. 4a . The uptake of 111 In-DOTA-Abegrin™ in U87MG tumors increased steadily from 4 h to 72 h p.i and then decreased from 72 h to 168 h p.i.(tumor uptake value was 6.19±1.16, 14.12±0.44, 14.85±4.73, 11.47±3.51, and 11.40±0.07%ID/g at 4, 24, 72, 120, and 168 h, respectively).
Radioactivity levels of 111
In-DOTA-Abegrin™ in blood were 31.31±7.16%ID/g at 4 h p.i, followed by a rather rapid clearance by the end of 168 h (1.17±1.02%ID/g).
111
In-DOTA-Abegrin™ also showed predominant liver and spleen uptake, while the kidney uptake was relatively low. At 72 h p.i, the uptake of In-DOTA-Abegrin™ was detected by blocking study. The coinjection of an excess dose of cold Abegrin™ with 111 In-DOTA-Abegrin™ resulted in a significantly reduced tumor uptake at 24 h p.i. (from 14.12 ± 0.44 to 6.93 ± 0.94%ID/g, n =4, P G0.01), indicating that the radioactivity uptake in U87MG tumors was at least partially integrin α v β 3 -mediated. The cold Abegrin™ did not totally block the tumor uptake of 111 In-DOTA-Abegrin™, which might be caused by the nonspecific targeting of large molecules, e.g., enhanced permeability and retention (EPR) effect [31] . The blocking study did not significantly affect the radioactivity uptake in other normal organs, such as heart, liver, and spleen, demonstrating that
In-DOTA-Abegrin™ did not specifically target the normal organs. The blood uptake also decreased after blocking, which might result from the enhanced blood clearance of 111 In-DOTA-Abegrin™ when coinjected with an excess dose of Abegrin™ (Fig. 4b) .
Discussion
In the present study, the in vitro and in vivo integrin α v β 3 targeting properties of Abegrin™, a fully humanized monoclonal antibody against integrin α v β 3 , was investigated, and the 111 In-labeled Abegrin™ ( 111 In-DOTA-Abegrin™) was evaluated as a SPECT tracer for molecular imaging of integrin α v β 3 expression.
Recently, Cai et al. investigated the effect of DOTA conjugation with different DOTA/Abegrin™ reaction ratios (20:1, 50:1, 100:1, 200:1, and 1,000:1) on the tumor uptake of the resulting 64 Cu-labeled Abegrin™ [21] . The result showed that the ratio of 200:1 was enough for the conjugation and radiolabeling. We conjugated Abegrin™ with DOTA at a reaction ratio of 200:1 for 111 In labeling, and the result revealed that the conjugation of DOTA under this condition did not impair the integrin α v β 3 binding specificity and affinity of Abegrin™ (Fig. 1c) . It has been well documented for the relatively low in vivo thermodynamic and kinetic stability of 64 Cu-DOTA [32] [33] [34] . The instability of the 64 Cu-DOTA conjugates would result in demetallization and subsequent accumulation in nontarget tissues such as liver [35] . Compared with 64 Cu-DOTAAbegrin™, the liver uptake of 111 In-DOTA-Abegrin™ was significantly reduced, possibly because the DOTA-chelating ability for 111 In is much stronger than that for 64 Cu. Integrin α v β 3 is highly expressed not only on some tumor cells but also on the activated endothelial cells of the newborn blood vessels [7, 36] . U87MG (human integrin α v β 3 -positive) and HT-29 (human integrin α v β 3 -negative) tumor cells were inoculated into nude mice; therefore, the two tumor tissues both expressed murine integrin α v β 3 on the tumor neovasculature (Fig. 2c) . Abegrin™ cross-reacts with integrin α v β 3 originated from rabbit, chicken, and hamster, but not from mouse [21] so Abegrin™ can recognize only the human integrin α v β 3 on the tumor cells but not the murine integrin α v β 3 on the tumor vasculature. In the human integrin α v β 3 -negative HT-29 tumors, FITC-Abegrin™ almost accumulated around the tumor vasculature (Fig. 3b) , which was most likely due to the nonspecific targeting of EPR (enhanced permeability and retention [31, 37] ) effect of tumors, instead of specific tumor vasculature targeting. In the human integrin α v β 3 -positive U87MG tumors, besides the specific targeting of Abegrin™ to the tumor cells, a large amount of antibody molecules also remained untargeted to the vasculature (Fig. 3b) , indicating that the accumulation of Abegrin™ in integrin α v β 3 -positive tumors was caused by both specific and nonspecific targeting.
Comparing with radiolabeled RGD tracers,
111
In-labeled anti-integrin α v β 3 antibody exhibited a quite different pharmacokinetics, such as the slower blood clearance, higher liver and spleen uptake, and high passive tumor targeting. The high nonspecific targeting of Abegrin™ in tumors reminds that caution should be taken when using 111 In-DOTA-Abegrin™ as a noninvasive imaging agent to directly quantify the integrin α v β 3 expression level in vivo. Aerts et al. recently found a disparity between the tumor uptake of 89 Zr-labeled anti-EGFR antibody cetuximab and in vivo EGFR expression on tumors [38] , which may be due to the complex microenvironment of tumors (e.g., inadequate vasculature and perfusion). In another report [39] , the tumor uptake of 111 In-labeled anti-HER2 antibody trastuzumab showed much stronger, nonlinear associations with HER2 density if it was corrected for nonspecific IgG localization (r 2 = 0.99), but without the correction, the association between HER2 density and tumor uptake was poor (r 2 = 0.22). Therefore, further study using 111 In-labeled IgG or HSA as the nonspecific imaging agents to quantify the nonspecific uptake values in different tumor models may be helpful for quantitatively measuring the specific targeting values of 111 In-DOTA-Abegrin™, which would provide more information on the receptor expression levels.
It also should be noted that the in vivo targeting property of 111 In-DOTA-Abegrin™ in the present study may not truly reflect the clinical situation because Abegrin™ does not bind the murine integrin α v β 3 expressed on tumor newbone vasculatures of mice. In human, Abegrin™ would bind both integrin α v β 3 -positive tumor cells and the activated endothelial cells in tumor blood vessels. The high human integrin α v β 3 binding affinity and specificity of 111 In-DOTA-Abegrin™ as demonstrated in this study guarantee that 111 In-DOTA-Abegrin™ is promising for both integrin α v β 3 -positive tumors imaging and tumor angiogenesis imaging in clinic.
In conclusion, 111 In-labeled Abegrin™ exhibited high in vitro specificity and immunoreactivity against integrin α v β 3 on tumor cells. Due to the specific receptor targeting, the in vivo uptake of 111 In-DOTA-Abegrin™ in integrin α v β 3 -positive tumors was significantly higher than that in integrin α v β 3 -negative tumors. The human integrin α v β 3 -specific targeting of 111 In-DOTA-Abegrin™ may be translated to clinic for noninvasive measurement of integrin α v β 3 in the tumors and also providing essential information in the evaluation of Abegrin™-based antiangiogenic therapy, as well as 90 Y-Abegrin™-based radioimmunotherapy.
